Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to ...

Johnson & Johnson filed a lawsuit against Samsung Bioepis for allegedly breaching their agreement over the launch of ...

Samsung Bioepis has now allegedly sub-licensed its Stelara biosimilar rights to a health conglomerate, breaching a previous ...

Three ustekinumab biosimilars enter the US market, expanding access to more affordable options referencing Stelara ...

Last year marked an all-time record of 18 Food and Drug Administration (FDA) biosimilar approvals, bringing the total number ...